CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAxone BioSciences, Inc., an emerging clinical-stage biotechnology company focused on developing innovative drugs to restore neurological function, today announced that Lisa McKerracher, CEO, has received two noteworthy invitations. Dr. McKerracher will be a member of the Leader’s Council for the Tannenbaum Open Science Program at McGill University, and at Rutgers University, she will be a speaker at their Spring Rutgers Women in Neuroscience (RUWINS) seminar.
For McGill, Dr. McKerracher will be an active member of Leader’s Council for Tannenbaum Open Science Program. Her role consists of brokering, fostering, and nurturing relationships to guide the Montreal Neurological Institute’s (MNI) transformative journey to become the first Open Science (OS) institute in the world, and to promote the cause of OS to accelerate scientific discovery and adoption.
At Rutgers, Dr. McKerracher will be presenting on March 2nd in the Nelson Biological Labs. The purpose of RUWINS is to bring outstanding women neuroscientists to Rutgers and to train young women in leadership.
“It is an honor for me to be a part of two highly respected academic institutions where I can assist others trying to make an impact in the science field, just like BioAxone has done in the neurological field,” said Lisa McKerracher, CEO, BioAxone BioSciences. “I look forward to collaborating with members from both Universities and advancing the output of scientific innovations.”
About BioAxone BioSciences
BioAxone BioSciences is a
clinical-stage biotechnology company based in Cambridge, MA, and is
developing innovative drugs to restore neurological function for
patients with Spinal Cord Injuries (SCI) and vascular malformations in
the central nervous system with unmet medical need, and glaucoma.
BioAxone is led by a team of scientists renowned for their work on axon
regeneration and neuronal signaling pathways. For more information,
visit http://www.bioaxonebio.com
and follow the company on Twitter at @BioAxone.
